A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Status:
Withdrawn
Trial end date:
2021-11-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended
phase 2 dose (RP2D) for TAK-659 when administered in combination with NKTR-214.